BMS-195614
Code | Size | Price |
---|
TAR-T26853-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T26853-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
BMS614 is a neutral retinoic acid receptor (RAR) α-selective antagonist (Ki = 2.5 nM).
CAS:
182135-66-6
Formula:
C29H24N2O3
Molecular Weight:
448.522
Purity:
0.98
SMILES:
CC1(C)CC=C(c2cnc3ccccc3c2)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O
References
1. Idres N, Beno?t G, Flexor MA, Lanotte M, Chabot GG. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites. Cancer Res. 2001 Jan 15;61(2):700-5. PubMed PMID: 11212271.
2. Vivat V, Zechel C, Wurtz JM, Bourguet W, Kagechika H, Umemiya H, Shudo K, Moras D, Gronemeyer H, Chambon P. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers. EMBO J. 1997 Sep 15;16(18):5697-709. PubMed PMID: 9312028; PubMed Central PMCID: PMC1170201.